Can pharmacogenomics improve malaria drug policy?
Mary W Roederer, Howard McLeod & Jonathan J Juliano

Abstract Coordinated global efforts to prevent and control malaria have been a tour-de-force for public health, but success appears to have reached a plateau in many parts of the world. While this is a multifaceted problem, policy strategies have largely ignored genetic variations in humans as a factor that influences both selection and dosing of antimalarial drugs. This includes attempts to decrease toxicity, increase effectiveness and reduce the development of drug resistance, thereby lowering health care costs. We review the potential hurdles to developing and implementing pharmacogenetic-guided policies at a national or regional scale for the treatment of uncomplicated falciparum malaria. We also consider current knowledge on some component drugs of artemisinin combination therapies and ways to increase our understanding of host genetics, with the goal of guiding policy decisions for drug selection.

Introduction
Renewed efforts to control and eliminate malaria are making advances using the current generation of tools: long-lasting insecticide treated nets, artemisinin combination therapies (ACTs) and indoor residual spraying. Despite gains made by bednets and spraying, malaria control and elimination efforts will continue to rely heavily on chemotherapy and, in particular, ACTs.

Currently, the World Health Organization (WHO) endorses four ACT combinations for uncomplicated falciparum malaria in non-pregnant adults (Table 1).1 In 2001, WHO recommended the use of ACTs due to high efficacy rates and potential to reduce the development of resistance.2 By 2009, 88 countries, including every country in Africa, had officially adopted ACTs as first-line agents for uncomplicated malaria.3 Despite the official guidelines, only 14 countries report distributing enough ACTs to treat at least 50% of reported malaria cases in the public system, and only 5 countries reported distributing enough ACTs to treat all cases in 2008.4 Over the next 5–10 years, an increasing number of patients, including children and pregnant women, will be given ACT therapy.

Combination therapies
Combination therapy, already in use for tuberculosis and HIV, is now recommended for malaria treatment to stem the tide of resistance and protect the widely available, highly efficacious class of drugs, the artemisinins. These combinations are based on the unlikely probability of a parasite becoming resistant simultaneously to two drugs with unrelated modes of action.5 With this in mind, the artemisinins are particularly good partner drugs for other antimalarials as they eliminate parasites rapidly from the blood and thereby limit the number of parasites exposed to the longer acting partner drug.

An example of host genetics
The success of drug therapy is dependent upon many contributing factors, including adherence to prescribed therapy, incorrect or suboptimal dosing, general health status and interactions with other drugs. Another crucial aspect of the lack of effectiveness (often due to low drug levels) and tolerability (often due to high drug levels) of chemotherapy is the way individuals metabolize the drug. Although the widespread use of modern antimalarials began in the 1940s, there was limited data about the absorption–distribution–metabolism–excretion parameters of antimalarials in humans until about 20 years ago.

The use of primaquine in the 1950s highlights the importance of pharmacogenetics for antimalarials, as severe reactions to the drug led to the discovery of glucose-6-phosphate dehydrogenase (G6PD) deficiency in 1956.6,7 The genetic variants among people with G6PD still confound our ability to develop effective antimalarials, illustrated by the withdrawal of the drug Lapdap® (chlorproguanil/dapsone) in 2008.7 This deficiency remains a cause for concern, as primaquine is used widely for terminal prophylaxis and to decrease transmission intensity by limiting reproduction of the malaria parasites.8

Certainly, scientists have investigated the contribution of parasite genetics, in particular relating to drug resistance. Several mutations in parasite drug target genes have been identified and associated with in vivo resistance to artemisinin partner drugs mefloquine, lumefantrine, amodiaquine and chlorproguanil.9–11 In addition to parasite genetics, host genetics canvaluably inform national drug policy decisions for first-line antimalarials.

Selection of ACTs
New pharmacology data available for modern antimalarials has helped to identify the major metabolic pathways and to identify human genetic variations that affect the ability to metabolize these agents (Table 2). Beyond the case of G6PD, there remain numerous questions about the role that pharmacogenetics can play to predict adverse drug reactions to antimalarials. Clearly, point-of-care testing for genetic variants, such as those of the CYP2C8 gene, is far from a reality in the developing world. However, it is possible that
pharmacogenetics could help inform drug formulary decisions on a regional or national scale.

Currently, national malaria control programmes select the most appropriate drugs for use in the respective country based upon costs, in vitro *Plasmodium falciparum* resistance patterns and the risk of adverse drug reactions. Very little attention has been paid to host genetics and their potential to affect major formulary decisions by decreasing toxicity, increasing efficacy and improving the time in the therapeutic range to combat resistance. This is especially important when ministries of health, national medicines review authorities or national malaria control programmes must choose between seemingly equal drugs without the aid of comprehensive local pharmacogenetic data. Importantly, knowledge of genetic differences in populations could reduce costs by decreasing adverse events and increasing efficacy of drugs.

This paper looks at drugs commonly used as part of ACTs to treat uncomplicated falciparum malaria in adults and provides specific examples of how genetics may affect drug efficacy and toxicity at a population level. It does not serve as an exhaustive review of all relationships between host genetics and antimalarial drugs. Several high-quality comprehensive reviews have been done elsewhere.\(^1\)

### Table 1. WHO-recommended antimalarial regimens\(^1\)

<table>
<thead>
<tr>
<th>Regimen</th>
<th>Artemisinin</th>
<th>Partner antimalarial drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>AL</td>
<td>artemether</td>
<td>Lumefantrine</td>
</tr>
<tr>
<td>AS+ AQ</td>
<td>artesunate</td>
<td>Amodiaquine</td>
</tr>
<tr>
<td>AS+ MQ</td>
<td>artesunate</td>
<td>Mefloquine</td>
</tr>
<tr>
<td>AS+ SP</td>
<td>artesunate</td>
<td>Sulfadoxine-pyrimethamine</td>
</tr>
</tbody>
</table>

### Table 2. Human genetic variants important for antimalarial metabolism\(^1\)

<table>
<thead>
<tr>
<th>Gene</th>
<th>Phenotype</th>
<th>Phenotype frequency in African populations (%)</th>
<th>Phenotype frequency in Asian populations (%)</th>
<th>Phenotype frequency in white populations (%)</th>
<th>First-line antimalarial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug metabolizing enzymes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2A6</td>
<td>Poor metabolizer</td>
<td>2</td>
<td>4–12</td>
<td>1</td>
<td>artesunate</td>
</tr>
<tr>
<td>CYP2C8</td>
<td>Poor metabolizer</td>
<td>1.5–4</td>
<td>&lt;0–1</td>
<td>2</td>
<td>amodiaquine</td>
</tr>
<tr>
<td>CYP3A5</td>
<td>Poor metabolizer with residual CYP3A5 activity</td>
<td>12–40</td>
<td>60–75</td>
<td>85–95</td>
<td>artemether, lumefantrine, mefloquine</td>
</tr>
<tr>
<td>CYP3A5</td>
<td>Poor metabolizer with no CYP3A5 activity</td>
<td>10–22</td>
<td>0</td>
<td>0</td>
<td>artemether, lumefantrine, mefloquine</td>
</tr>
<tr>
<td>UGT1A9</td>
<td>Poor metabolizer</td>
<td>&lt;0–1</td>
<td>unknown</td>
<td>≤1</td>
<td>DHA</td>
</tr>
<tr>
<td>UGT2B7</td>
<td>Poor metabolizer</td>
<td>4–10</td>
<td>6–7</td>
<td>20–25</td>
<td>DHA</td>
</tr>
<tr>
<td>Drug transporters</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABCB1</td>
<td>Reduced function</td>
<td>21</td>
<td>40–45</td>
<td>46–56</td>
<td>mefloquine</td>
</tr>
<tr>
<td></td>
<td>Higher concentration of drug substrate</td>
<td>&lt;1–16</td>
<td></td>
<td></td>
<td>mefloquine</td>
</tr>
</tbody>
</table>

DHA, dihydroartemisin

### Genetics to guide drug policy

#### The case of amodiaquine

The antimalarial amodiaquine is generally well tolerated, but its use in primarily Caucasian populations in the 1980s and 1990s was associated with high rates of agranulocytosis (1 in 2100 with a case fatality rate of 1 in 31 000) and hepatotoxicity (1 in 15 600). WHO removed amodiaquine from the Essential Medicines List due to the discovery of these toxicities, but it was added back on the list in the late 1990s as resistance to alternative drugs began to appear. Recent evidence points to frequent mild adverse events caused by amodiaquine. A trial in 15 subjects in Africa evaluating the pharmacokinetics of amodiaquine and the combination of amodiaquine and artesunate revealed the common adverse events of hepatotoxicity and leukopenia after just two doses given three weeks apart.\(^2\)

People with mutant genotypes of CYP2C8, CYP1A1 and CYP1B1 have been found to have immunogenic adverse reactions to amodiaquine.\(^2\)\(^3\)–\(^2\)\(^6\) Wide variations in the CYP2C8 genotype mean that individuals experience broad differences in the drug’s efficacy and toxicity. Evidence suggests that decreased function of the CYP2C8 enzyme impairs metabolism of the drug and can form a toxic metabolite that...
Fig. 1. World map showing frequencies of the CYP2C8*2 allele in different populations

Fig. 2. World map showing frequencies of the CYP2C8*3 allele in different populations

x = allele frequency in reference population (US caucasians), y = allele frequency in country with data
causes hepatotoxicity and agranulocytosis. Two more common CYP2C8 variants, CYP2C8*2 and *3, decrease the metabolizing ability of CYP2C8 as evidenced by reduced clearance of the anticancer drug paclitaxel and arachidonic acid, respectively. In fact, CYP2C8*3 displays no detectable metabolizing ability in vitro.

In a study by Parikh et al., 275 subjects with malaria from Burkina Faso were evaluated for amodiaquine metabolism. The subjects with the CYP2C8*2 genotype (more common African variant) experienced more abdominal pain than subjects with the wild-type (i.e. the normal, non-mutated gene) (52% versus 30%; \( P < 0.01 \)). Other adverse effects did not differ. However, as in many pharmacogenetic studies, this study used a rather small sample to evaluate rare toxicities and did not test for liver function change as a marker for hepatotoxicity or pharmacokinetic changes to test for drug concentrations or toxic intermediates. Studies in Burkina Faso and Ghana have not revealed a relationship between drug efficacy and CYP2C8 genotype.

While the percentage of the population with an inactivating CYP2C8 genetic variant is not high in most malaria-endemic regions, the overall incidence of risk is significant due to the burden of disease. For example, Cavaco et al. estimated that the CYP2C8*2 and CYP2C8*3 genetic variants occur in 2.1% of the population in Zanzibar, United Republic of Tanzania: this translates into more than 30,000 patients per year at risk for severe drug reactions to amodiaquine (of a malaria patient population of ~1,000,000).

### Ghana example

In Ghana, with a total population of more than 25 million, 5270108 cases of malaria were documented in 2007. The majority of these cases were likely treated with artesunate plus amodiaquine, the first-line treatment of choice on the Ghanaian Essential Medicines List. Based on a 1.5% population incidence of low-metabolizing CYP2C8, almost 80,000 (79,052) of these malaria cases would have occurred in low metabolizers (Fig. 1 and Fig. 2). Collecting data on adverse drug reactions and their cost is the best way to evaluate amodiaquine-related adverse effects. Without pharmacovigilance and cost data to model the medical costs associated with potential adverse drug reactions among these low metabolizers, giving this drug combination to 79,000 low metabolizers each year wastes an estimated 0.57 United States dollars per treatment course (average cost per treatment ranges from US$ 0.57–0.88), a total of approximately US$ 45,000 a year.

The known literature on CYP2C8 allele (gene) frequencies reveals a lack of data in malaria-endemic Africa but, in those African countries with data, there is a higher frequency than in American Caucasians (Fig. 1, Fig. 2 and Table 2). With the Ghana example showing a loss of more than US$ 45,000, the national control programme or national medicines review authority could choose an alternative from the three first-line antimalarial combinations to treat malaria.

### Artemisinins

The artemisinins as a group differ in the routes they take in the human body to convert to the major active metabolite, dihydroartemisinin (DHA). Artesunate undergoes rapid and extensive conversion via CYP2A6 and, to a lesser extent, CYP2B6 and CYP1A1 and CYP1A2. Almost 40 gene variants for CYP2A6 have been identified; at least 13 of these show decreased metabolizing function and five show no activity in vivo. The major antimalarial activity of artemesate is performed by DHA. People with poorly functioning CYP2A6 will have higher concentrations of artemesate and lower concentrations of DHA. This could reduce the drug’s antimalarial activity, kill fewer parasites and increase the potential for artemesate resistance.

Malaria endemicity is high in many areas of sub-Saharan Africa, such as Ghana. In contrast, in the Sabah region of Malaysia (which has the highest endemicity for malaria in this region) the burden of disease is considerably less than in Ghana. Almost two thirds of a Ghanaian population exhibited the wild-type genotype of CYP2A6 with more than 80% allele frequency of CYP2A6*1A. In contrast, a Malaysian population had an observed frequency for wild-type genotype of only 8% and an allele frequency for CYP2A6*1A of approximately 32%. With wild-type resistant alleles for the majority of Ghanaian CYP2A6 activity, artemesate conversion to DHA and antimalarial activity are expected to be normal. In the Malaysian population with a low wild-type genotype frequency, CYP2A6 activity is decreased, the conversion to DHA decreased, and the antimalarial activity of artemesate may be compromised. Studies in other Asian populations also reveal a high frequency of non-wild-type alleles and an especially high frequency of the alleles that translate to no CYP2A6 activity (11.5–20.1% for Chinese, Japanese, Korean and Thai people).

Resistance to artemisinin-based therapies is emerging in Thailand and approaches 10% in some areas. While not established, a potential contributor to artemisinin resistance in Thailand may be related to CYP2A6 activity (at least 14% frequency of the CYP2A6 alleles with no activity) and the inability to convert artesunate to DHA.

### Table 3. Potential drug–gene relationships for first-line treatments of uncomplicated falciparum malaria in non-pregnant adults

<table>
<thead>
<tr>
<th>Drug</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>Artesunate</td>
<td>CYP2B6</td>
</tr>
<tr>
<td></td>
<td>UGT1A9</td>
</tr>
<tr>
<td></td>
<td>UGT2B7</td>
</tr>
<tr>
<td>Artemether</td>
<td>CYP3A4/5</td>
</tr>
<tr>
<td></td>
<td>CYP2C8</td>
</tr>
<tr>
<td></td>
<td>UGT1A9</td>
</tr>
<tr>
<td></td>
<td>UGT2B7</td>
</tr>
<tr>
<td>Amodiaquine</td>
<td>CYP2C8</td>
</tr>
<tr>
<td></td>
<td>ABCB1</td>
</tr>
<tr>
<td>Mefloquine</td>
<td>ABCB1</td>
</tr>
<tr>
<td>Sulodexone/pyrimethamine</td>
<td>No data</td>
</tr>
<tr>
<td>Lumefantrine</td>
<td>No data</td>
</tr>
</tbody>
</table>

*Fig. 1*

*Fig. 2*

*Table 2*
What next?

Our understanding of the host factors contributing to the effectiveness of antimalarials is still in its infancy. As a community we need to determine ways to enhance our ability to study the pharmacokinetics and pharmacogenetics of antimalarials to help decrease the burden imposed by drug toxicity and to help protect their longevity. We can do this in three main ways: (i) integrating pharmacogenetic studies with the pharmacokinetic studies of antimalarials; (ii) increasing the generation of human genetic data and (iii) enhancing the infrastructure for pharmacogenetic research of antimalarial use in endemic countries.

Integrating research

Much of the data concerning the pharmacogenetics of antimalarials is derived from small and under-powered studies conducted in a retrospective manner. In particular, we are lacking significant data for some ACT partner drugs, such as sulfadoxine-pyrimethamine and lumefantrine. A resurgent interest in the pharmacology and pharmacokinetics of antimalarials in the malaria drug resistance community has spurred the development of another potential new resource for gathering pharmacogenetic data. As part of the Worldwide Antimalarial Resistance Network, a module has been developed to improve the quality of antimalarial pharmacology data generated, to use the new information to define drug resistance and to inform optimal dosing schedules. The goal is to facilitate global cooperation between groups active in the antimalarial pharmacology field (available at: http://www.wwarn.org). Pharmacology researchers, especially pharmacokinetic researchers, of antimalarials should obtain informed consent from study participants to allow use of their samples for collaborative pharmacogenetic analysis, either prospectively or in future retrospective analyses.

Generating data

Another potential resource for increasing our understanding of the pharmacogenetics of antimalarials are national control programmes, and the researchers and funding agencies associated with these programmes. During in vivo monitoring and efficacy studies carried out by these groups, samples obtained as dried blood spots are often collected and stored. The amount of DNA collected in these samples would not allow for assessment of a large number of genetic variations but it could allow for targeted testing of a small number that are vetted in strong pharmacogenetic studies. The key would be to encourage these groups to obtain consent from patients for retrospective human DNA testing. For example, considering the four first-line treatments, blood spots could provide a way to use pharmacogenetics to prioritize pharmacotherapy based on genetic differences within a defined population and to evaluate CYP2C8 genetics. Since amodiaquine requires CYP2C8 for metabolism to an active agent, national control programmes or the national medicines review authorities could use genotype frequencies in that population to determine the priority of a regimen containing amodiaquine.

Enhanced infrastructure

Ethnic variability is known for its association with antimalarial metabolism, but genetic data are missing for much of the world's population. An increasing number of resources and efforts has been put into place to help with gathering information about the genetic make-up of different ethnic groups. In malaria-endemic areas, there are no pharmacogenetics organizations, such as the National Institute of Genomic Medicine (INMEGEN) in Mexico, to evaluate population genetic differences. However, the ideas explored in the white paper, Harnessing genomic technologies towards improving health in Africa, detail the systematic process for improving the research infrastructure in Africa.15

There is a strong need for genetic research in Africa. The overarching needs are for infrastructure, education and training, disease-related research and a comprehensive and continued focus on ethical, legal and social issues. To address these needs the Human Health and Heredity in Africa Initiative aims to integrate pharmacogenetics in the selection of national formularies in Africa.

In the meantime, to address the gap in knowledge and need for resources to evaluate genetic differences in developing countries, the Pharmacogenetics for Every Nation Initiative (PGENI) plans to sample 500 people from every ethnic group that represents 10% or more of the population in 104 developing countries.24,42 To avoid any conflicts of interest, PGENI declines funding from any drug manufacturers. PGENI aims to start the development of basic genetic knowledge in traditionally underserved environments. With the generation of medication prioritization algorithms for diseases of global importance, PGENI produces country-specific, genetically-enhanced treatment algorithms for diseases such as malaria. Using known genetic information and the WHO recommended treatment for uncomplicated malaria, a prioritization algorithm includes entry points where pharmacogenetics may augment decision-making, such as for CYP2C8 and CYP2A6 polymorphism frequencies when evaluating the use of amodiaquine and artesunate, respectively. When considering local parasite resistance and drug costs, the pharmacogenetically-enhanced, medical decision-making algorithm becomes a practical mechanism for weighing the options for formulary inclusion or exclusion by national medicines review authorities or national control programmes.

Countries such as the United Kingdom of Great Britain and Northern Ireland and the United States of America have made tremendous investments in research towards genomic medicine. However, in parts of the world where national health expenditures are as low as US$ 30 a day, the investment in genomic research has been extremely low.44 Importantly however, some malaria-endemic countries, such as India, South Africa and Thailand, have begun to invest in large-scale studies of human genomic variation.45,46 In addition, smaller projects, such as the DNA data bank in the Gambia and a biobank and pharmacogenetics database in Harare, Zimbabwe, are emerging and may be able to provide valuable data to inform national control programmes and medicines review authorities.47,48

Make it practical

While research is necessary to develop an objective strategy, individualized antimalarial therapy based on genetics will not be practical in most endemic countries for decades. However, that should not prevent the application of pharmacogenetic knowledge in public policy decisions. Just as regional sam-
As the pharmacogenetic markers with significant impact on drug response and/or toxicity are vetted, using the malaria control programme samples in malaria-endemic countries provides a good first step to expanding the potential to impact global drug use through improved efficacy and decreased drug toxicity. This should help to populate a map of pharmacogenetic data to guide national formulary decision-making by using existing samples, data and processes.

Conclusion

To accomplish the considerable goal of developing pharmacogenetically-informed drug policies, there is a need for strong collaboration between parasitologists studying parasite resistance, public health officials from control programmes and researchers identifying genetic causes of differences in drug toxicity and efficacy. The African Medicines Regulatory Harmonization Initiative will provide a regional regulatory process and may allow improvements not only at the national but also at the regional level.49 These collaborations, in conjunction with others investigating new drug entities, may help to affect the delivery of care to real patients in malaria-endemic regions. The work to create collaborations and to develop systems that allow for sampling large populations to establish a map of genetic differences will not be easy, but it is certainly worthwhile to include pharmacogenetic information when considering the data and defining the limited number of drugs that will be available to a population.

Acknowledgements

Jonathan J Juliano was supported by award number KL2RR025746 from the National Center for Research Resources, National Institutes of Health, USA. This work is part of the Pharmacogenetics for Every Nation Initiative. Mary W Roederer and Howard McLeod complete research with PGENI.

Competing interests: None declared.

ملخص

هل يمكن للعلم الجينوميات الدوائي أن يحسن من السياسات الدوائية للملاريا؟

لم تحقق الجهود العالمية المنسقة نجاحاً باهراً في الوقاية من الملاريا ومكافحتها، ولكن الشيء المثير للإثارة هو أن هناك بنية كافية للFLASHES التي يمكنها أن تكون مجموعة عالمية لتحديد التغيرات الجينية وتحديد الأدوية المحافظة على الذكاء السكاني. التهديدات الخطرة يجب أن يضغط على صانعي السياسات نحو اختيار الدواء. 

Résumé

La pharmacogénomique peut-elle améliorer la politique des médicaments contre le paludisme?

Les efforts mondiaux coordonnés de prévention et de lutte contre le paludisme ont été un véritable tour de force pour la santé publique, mais le succès semble avoir atteint un plateau dans de nombreuses régions du monde. Bien que ce soit un problème à multiples facettes, les stratégies politiques ont largement ignoré les variations génétiques chez l’homme en tant que facteur influençant à la fois la sélection et le dosage des médicaments antipaludiques. Cela inclut des tentatives pour diminuer la toxicité, augmenter l’efficacité et réduire le développement de la résistance aux médicaments, réduisant ainsi les coûts des soins de santé. Nous passons en revue les obstacles potentiels au développement des initiatives futures.
et à la mise en œuvre des politiques guidées par la pharmacogénétique à l'échelle nationale ou régionale pour le traitement du paludisme non compliqué à falciparum. Nous examinons également les connaissances actuelles sur certains médicaments qui composent les combinaisons thérapeutiques à base d'artémisine et les moyens d'accroître notre compréhension de la génétique de l'hôte, dans l'objectif d'orienter les décisions politiques de sélection des médicaments.

Резюме

Можно ли с помощью фармакогеномики улучшить политику в области противомалярийных препаратов?

Скоординированные глобальные усилия по профилактике малярии и борьбе с этой болезнью стали важным достижением в сфере общественного здравоохранения. Однако во многих странах мира поступательное движение в этой области, по-видимому, затормозилось. Эта проблема имеет много аспектов, однако в политических стратегиях в значительной степени игнорировались генетические вариации людей как фактор, влияющий на выбор и дозирование противомалярийных препаратов. Учет этого фактора включает в себя попытки снизить токсичность, повысить эффективность и ограничить развитие лекарственной устойчивости, уменьшив тем самым расходы на медико-санитарную помощь. Мы исследуем потенциальные препятствия на пути разработки и внедрения политических мер, опирающихся на фармакогенетику, в общенациональном и региональном масштабе для лечения несложных случаев заболевания тропической малярией. Мы также рассматриваем накопленные в настоящее время знания о некоторых многокомпонентных лекарственных препаратах, применяемых в рамках артемизин-комбинированной терапии, а также способы углубления нашего понимания генетики хозяина с целью руководства политическими решениями в области подбора лекарств.

Resumen

¿Puede mejorar la farmacogenómica la política de fármacos contra la malaria?

Los esfuerzos coordinados que se están realizando en todo el mundo para prevenir y controlar la malaria han sido una auténtica hazaña para la salud pública, pero parece que el éxito conseguido se ha estabilizado en muchas partes del mundo. Debido a que se trata de un problema multifacético, muchos de las estrategias de las políticas han ignorado las variaciones genéticas en humanos como un factor que influye tanto en la selección como en las dosis de fármacos antimaláricos. Esto incluye los intentos de reducir la toxicidad, de aumentar la eficacia y de disminuir el desarrollo de resistencia a los fármacos. De esta manera, también se reducirán los costes de la asistencia sanitaria. Revisamos los posibles obstáculos para el desarrollo e implementación de las políticas orientadas a la farmacogenética a nivel nacional o regional para el tratamiento de la malaria por Plasmodium falciparum sin complicaciones.

Con el objetivo de conseguir orientación para las decisiones sobre la selección de fármacos, también tenemos en cuenta los conocimientos disponibles sobre algunas terapias de combinación de fármacos componentes de artemisinina y las maneras de aumentar nuestros conocimientos sobre genética del huésped.

References
